Market Players Developing iPS Cell Therapies – BioInformant
By raymumme
1. Cellular Dynamics International, Owned by FujiFilm Holdings
Founded in 2004 and listed on NASDAQ in July 2013, Cellular Dynamics International (CDI) is headquartered in Madison, Wisconsin. The company is known for its extremely robust patent portfolio containing more than 900 patents.
According to the company, CDI is the worlds largest producer of fully functional human cells derived from induced pluripotent stem (iPS) cells.[1] Their trademarked, iCell Cardiomyocytes, derived from iPSCs, are human cardiac cells used to aid drug discovery, improve the predictability of a drugs worth, and screen for toxicity. In addition, CDI provides: iCell Endothelial Cells for use in vascular-targeted drug discovery and tissue regeneration, iCell Hepatocytes, and iCell Neurons for pre-clinical drug discovery, toxicity testing, disease prediction, and cellular research.[2]
Induced pluripotent stem cells were first produced in 2006 from mouse cells and in 2007 from human cells, by Shinya Yamanaka at Kyoto University,[3] who also won the Nobel Prize in Medicine or Physiology for his work on iPSCs.[4] Yamanaka has ties to Cellular Dynamics International as a member of the scientific advisory board of iPS Academia Japan. IPS Academia Japan was originally established to manage the patents and technology of Yamanakas work, and is now the distributor of several of Cellular Dynamics products, including iCell Neurons, iCell Cardiomyocytes, and iCell Endothelial Cells.[5]
Importantly, in 2010 Cellular Dynamics became the first foreign company to be granted rights to use Yamanakas iPSC patent portfolio. Not only has CDI licensed rights to Yamanakas patents, but it also has a license to use Otsu, Japan-based Takara Bios RetroNectin product, which it uses as a tool to produce its iCell and MyCell products.[6]
Furthermore, in February 2015, Cellular Dynamics International announced it would be manufacturing cGMP HLA Superdonor stem cell lines that will support cellular therapy applications through genetic matching.[8] Currently, CDI has two HLA super donor cell lines that provide a partial HLA match to approximately 19% of the population within the U.S., and it aims to expand its master stem cell bank by collecting more donor cell lines that will cover 95% of the U.S. population.[9] The HLA super donor cell lines were manufactured using blood samples and used to produce pluripotent iPSC lines, giving the cells the capacity to differentiate into nearly any cell within the human body.
On March 30, 2015, Fujifilm Holdings Corporation announced that it was acquiring CDI for $307 million, allowing CDI to continue to run its operations in Madison, Wisconsin, and Novato, California as a consolidated subsidiary of Fujifilm.[14] A key benefit of the merger is that CDIs technology platform enables the production of high-quality fully functioning iPSCs (and other human cells) on an industrial scale, while Fujifilm has developed highly-biocompatible recombinant peptides that can be shaped into a variety of forms for use as a cellular scaffold in regenerative medicine when used in conjunction with CDIs products.[15]
Additionally, Fujifilm has been strengthening its presence in the regenerative medicine field over the past several years, including a recent A$4M equity stake in Cynata Therapeutics and an acquisition of Japan Tissue Engineering Co. Ltd. in December 2014. Most commonly called J-TEC, Japan Tissue Engineering Co. Ltd. successfully launched the first two regenerative medicine products in the country of Japan. According to Kaz Hirao, CEO of CDI, It is very important for CDI to get into the area of therapeutic products, and we can accelerate this by aligning it with strategic and technical resources present within J-TEC.
Kaz Hirao also states, For our Therapeutic businesses, we will aim to file investigational new drugs (INDs) with the U.S. FDA for the off-the-shelf iPSC-derived allogeneic therapeutic products. Currently, we are focusing on retinal diseases, heart disorders, Parkinsons disease, and cancers. For those four indicated areas, we would like to file several INDs within the next five years.
Finally, in September 2015, CDI again strengthened its iPS cell therapy capacity by setting up a new venture, Opsis Therapeutics. Opsis is focused on discovering and developing novel medicines to treat retinal diseases and is a partnership with Dr. David Gamm, the pioneer of iPS cell-derived retinal differentiation and transplantation.
In summary, several key events indicate CDIs commitment to developing iPS cell therapeutics, including:
Australian stem cell company Cynata Therapeutics (ASX:CYP) is taking a unique approach by creating allogeneic iPSC derived mesenchyal stem cell (MSCs) on a commercial scale. Cynatas Cymerus technology utilizes iPSCs provided by Cellular Dynamics International, a Fujifilm company, as the starting material for generating mesenchymoangioblasts (MCAs), and subsequently, for manufacturing clinical-grade MSCs. According to Cynatas Executive Chairman Stewart Washer who was interviewed by The Life Sciences Report, The Cymerus technology gets around the loss of potency with the unlimited iPS cellor induced pluripotent stem cellwhich is basically immortal.
On January 19, 2017, Fujifilm took an A$3.97 million (10%) strategic equity stake in Cynata, positioning the parties to collaborate on the further development and commercialization of Cynatas lead Cymerus therapeutic MSC product CYP-001 for graft-versus-host disease (GvHD). (CYP-001 is the product designation unique to the GVHD indication). The Fujifilm partnership also includes potential future upfront and milestone payments in excess of A$60 million and double-digit royalties on CYP-001 product net sales for Cynata Therapeutics, as well as a strategic relationship for the potential future manufacture of CYP-001 and certain rights to other Cynata technology.
One of the key inventors of Cynatas technology is Igor Slukvin, MD, Ph.D., Scientific Founder of Cellular Dynamics International (CDI) and Cynata Therapeutics. Dr. Slukvin has released more than 70 publications about stem cell topics, including the landmark article in Cell describing the now patented Cymerus technique. Dr. Slukvins co-inventor is Dr. James Thomson, the first person to isolate an embryonic stem cell (ESC) and one of the first people to create a human induced pluripotent stem cell (hiPSC). Dr. James Thompson was the Founder of CDI in 2004.
There are three strategic connections between Cellular Dynamics International (CDI) and Cynata Therapeutics, which include:
Recently, Cynata received advice from the UK Medicines and Healthcare products Regulatory Agency (MHRA) that its Phase I clinical trial application has been approved, titled An Open-Label Phase 1 Study to Investigate the Safety and Efficacy of CYP-001 for the Treatment of Adults With Steroid-Resistant Acute Graft Versus Host Disease. It will be the worlds first clinical trial involving a therapeutic product derived from allogeneic (unrelated to the patient) induced pluripotent stem cells (iPSCs).
Participants for Cynatas upcoming Phase I clinical trial will be adults who have undergone an allogeneic haematopoietic stem cell transplant (HSCT) to treat a hematological disorder and subsequently been diagnosed with steroid-resistant Grade II-IV GvHD. The primary objective of the trial is to assess safety and tolerability, while the secondary objective is to evaluate the efficacy of two infusions of CYP-001 in adults with steroid-resistant GvHD.
Using Professor Yamanakas Nobel Prize-winning achievement of ethically uncontentious iPSCs and CDIs high-quality iPSCs as source material, Cynata has achieved two world firsts:
Cynata has also released promising pre-clinical data in Asthma, Myocardial Infarction (Heart Attack), and Critical Limb Ischemia.
There are four key advantages of Cynatas proprietary Cymerus MSC manufacturing platform. Because the proprietary Cymerus technology allows nearly unlimited production of MSCs from a single iPSC donor, there is batch-to-batch uniformity. Utilizing a consistent starting material allows for a standardized cell manufacturing process and a consistent cell therapy product. Unlike other companies involved with MSC manufacturing, Cynata does not require a constant stream of new donors in order to source fresh stem cells for its cell manufacturing process, nor does it require the massive expansion of MSCs necessitated by reliance on freshly isolated donations.
Finally, Cynata has achieved a cost-savings advantage through its unique approach to MSC manufacturing. Its proprietary Cymerus technology addresses a critical shortcoming in existing methods of production of MSCs for therapeutic use, which is the ability to achieve economic manufacture at commercial scale.
On June 22, 2016, RIKEN announced that it is resuming its retinal induced pluripotent stem cell (iPSC) study in partnership with Kyoto University.
2013 was the first time in which clinical research involving transplant of iPSCs into humans was initiated, led by Masayo Takahashi of the RIKEN Center for Developmental Biology (CDB) in Kobe, Japan. Dr. Takahashi and her team were investigating the safety of iPSC-derived cell sheets in patients with wet-type age-related macular degeneration. Although the trial was initiated in 2013 and production of iPSCs from patients began at that time, it was not until August of 2014 that the first patient, a Japanese woman, was implanted with retinal tissue generated using iPSCs derived from her own skin cells.
A team of three eye specialists, led by Yasuo Kurimoto of the Kobe City Medical Center General Hospital, implanted a 1.3 by 3.0mm sheet of iPSC-derived retinal pigment epithelium cells into the patients retina.[196] Unfortunately, the study was suspended in 2015 due to safety concerns. As the lab prepared to treat the second trial participant, Yamanakas team identified two small genetic changes in the patients iPSCs and the retinal pigment epithelium (RPE) cells derived from them. Therefore, it is major news that the RIKEN Institute will now be resuming the worlds first clinical study involving the use of iPSC-derived cells in humans.
According to the Japan Times, this attempt at the clinical study will involve allogeneic rather than autologous iPSC-derived cells for purposes of cost and time efficiency. Specifically, the researchers will be developing retinal tissues from iPS cells supplied by Kyoto Universitys Center for iPS Cell Research and Application, an institution headed by Nobel prize winner Shinya Yamanaka. To learn about this announcement, view this article from Asahi Shimbun, a Tokyo- based newspaper.
In November 2015 Astellas Pharma announced it was acquiring Ocata Therapeutics for $379M. Ocata Therapeutics is a biotechnology company that specializes in the development of cellular therapies, using both adult and human embryonic stem cells to develop patient-specific therapies. The companys main laboratory and GMP facility are in Marlborough, Massachusetts, and its corporate offices are in Santa Monica, California.
When a number of private companies began to explore the possibility of using artificially re-manufactured iPSCs for therapeutic purposes, one such company that was ready to capitalize on the breakthrough technology was Ocata Therapeutics, at the time called Advanced Cell Technology. In 2010, the company announced that it had discovered several problematic issues while conducting experiments for the purpose of applying for U.S. Food and Drug Administration approval to use iPSCs in therapeutic applications. Concerns such as premature cell death, mutation into cancer cells, and low proliferation rates were some of the problems that surfaced. [17]
As a result, the company shifted its induced pluripotent stem cell approach to producing iPS cell-derived human platelets, as one of the benefits of a platelet-based product is that platelets do not contain nuclei, and therefore, cannot divide or carry genetic information. While the companys Induced Pluripotent Stem Cell-Derived Human Platelet Program received a great deal of media coverage in late 2012, including being awarded the December 2012 honor of being named one of the 10 Ideas that Will Shape the Year by New Scientist Magazine,[178]. Unfortunately, the company did not succeed in moving the concept through to clinical testing in 2013.
Nonetheless, Astellas is clearly continuing to develop Ocatas pluripotent stem cell technologies involving embryonic stem cells (ESCs) and induced pluripotent stem cells (iPS cells). In a November 2015 presentation by Astellas President and CEO, Yoshihiko Hatanaka, he indicated that the company will aim to develop an Ophthalmic Disease Cell Therapy Franchise based around its embryonic stem cell (ESC) and induced pluripotent stem cell (iPS cell) technology. [19]
What other companies are developing iPSC derived therapeutics and products? Share your thoughts in the comments below.
BioInformant is the first and only market research firm to specialize in the stem cell industry. BioInformant research has been cited by major news outlets that include the Wall Street Journal, Nature Biotechnology, Xconomy, and Vogue Magazine. Serving Fortune 500 leaders that include GE Healthcare, Pfizer, and Goldman Sachs. BioInformant is your global leader in stem cell industry data.
Footnotes[1] CellularDynamics.com (2014). About CDI. Available at: http://www.cellulardynamics.com/about/index.html. Web. 1 Apr. 2015.[2] Ibid.[3] Takahashi K, Yamanaka S (August 2006). Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell 126 (4): 66376.[4] 2012 Nobel Prize in Physiology or Medicine Press Release. Nobelprize.org. Nobel Media AB 2013. Web. 7 Feb 2014. Available at: http://www.nobelprize.org/nobel_prizes/medicine/laureates/2012/press.html. Web. 1 Apr. 2015.[5] Striklin, D (Jan 13, 2014). Three Companies Banking on Regenerative Medicine. Wall Street Cheat Sheet. Retrieved Feb 1, 2014 from, http://wallstcheatsheet.com/stocks/3-companies-banking-on-regenerative-medicine.html/?a=viewall.%5B6%5D Striklin, D (2014). Three Companies Banking on Regenerative Medicine. Wall Street Cheat Sheet [Online]. Available at: http://wallstcheatsheet.com/stocks/3-companies-banking-on-regenerative-medicine.html/?a=viewall. Web. 1 Apr. 2015.[7] Cellular Dynamics International (July 30, 2013). Cellular Dynamics International Announces Closing of Initial Public Offering [Press Release]. Retrieved from http://www.cellulardynamics.com/news/pr/2013_07_30.html.%5B8%5D Investors.cellulardynamics.com,. Cellular Dynamics Manufactures Cgmp HLA Superdonor Stem Cell Lines To Enable Cell Therapy With Genetic Matching (NASDAQ:ICEL). N.p., 2015. Web. 7 Mar. 2015.[9] Ibid.[10] Cellulardynamics.com,. Cellular Dynamics | Mycell Products. N.p., 2015. Web. 7 Mar. 2015.[11]Sirenko, O. et al. Multiparameter In Vitro Assessment Of Compound Effects On Cardiomyocyte Physiology Using Ipsc Cells.Journal of Biomolecular Screening 18.1 (2012): 39-53. Web. 7 Mar. 2015.[12] Sciencedirect.com,. Prevention Of -Amyloid Induced Toxicity In Human Ips Cell-Derived Neurons By Inhibition Of Cyclin-Dependent Kinases And Associated Cell Cycle Events. N.p., 2015. Web. 7 Mar. 2015.[13] Sciencedirect.com,. HER2-Targeted Liposomal Doxorubicin Displays Enhanced Anti-Tumorigenic Effects Without Associated Cardiotoxicity. N.p., 2015. Web. 7 Mar. 2015.[14] Cellular Dynamics International, Inc. Fujifilm Holdings To Acquire Cellular Dynamics International, Inc.. GlobeNewswire News Room. N.p., 2015. Web. 7 Apr. 2015.[15] Ibid.[16] Cyranoski, David. Japanese Woman Is First Recipient Of Next-Generation Stem Cells. Nature (2014): n. pag. Web. 6 Mar. 2015.[17] Advanced Cell Technologies (Feb 11, 2011). Advanced Cell and Colleagues Report Therapeutic Cells Derived From iPS Cells Display Early Aging [Press Release]. Available at: http://www.advancedcell.com/news-and-media/press-releases/advanced-cell-and-colleagues-report-therapeutic-cells-derived-from-ips-cells-display-early-aging/.%5B18%5D Advanced Cell Technology (Dec 20, 2012). New Scientist Magazine Selects ACTs Induced Pluripotent Stem (iPS) Cell-Derived Human Platelet Program As One of 10 Ideas That Will Shape The Year [Press Release]. Available at: http://articles.latimes.com/2009/mar/06/science/sci-stemcell6. Web. 9 Apr. 2015.[19] Astellas Pharma (2015). Acquisition of Ocata Therapeutics New Step Forward in Ophthalmology with Cell Therapy Approach. Available at: https://www.astellas.com/en/corporate/news/pdf/151110_2_Eg.pdf. Web. 29 Jan. 2017.
Read the original here:
Market Players Developing iPS Cell Therapies - BioInformant
- 001 Ying Liu discusses IPS cell therapy for ALS [Last Updated On: August 6th, 2011] [Originally Added On: August 6th, 2011]
- 002 Jeanne Loring talks about stem cells, part 2 [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- 003 Embryonic Stem Cells From Skin: Making Old Cells Young [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- 004 IPs cells Part3 [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- 005 IPs cells Part 2 [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- 006 A Century of Stem Cells - Johns Hopkins Medicine [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- 007 Stem Cell Implications for ALS (Amyotrophic Lateral Sclerosis) [Last Updated On: September 7th, 2011] [Originally Added On: September 7th, 2011]
- 008 Myelin Repair Foundation on Stem Cell Research [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- 009 IPs Cells Part 4 [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- 010 National Medical Report [Last Updated On: September 13th, 2011] [Originally Added On: September 13th, 2011]
- 011 IPs cells Part 1 [Last Updated On: September 15th, 2011] [Originally Added On: September 15th, 2011]
- 012 iPS Stem Cell-Based Treatment of Epidermolysis Bullosa [Last Updated On: September 16th, 2011] [Originally Added On: September 16th, 2011]
- 013 Jeanne Loring talks about stem cells, part 1 [Last Updated On: September 16th, 2011] [Originally Added On: September 16th, 2011]
- 014 Kristopher Nazor 2 [Last Updated On: September 16th, 2011] [Originally Added On: September 16th, 2011]
- 015 Andalusian Stem Cell Bank [Last Updated On: September 19th, 2011] [Originally Added On: September 19th, 2011]
- 016 Cellular Reprogramming Stem Cell Domain Name For Sale! - CellularReprogramming.com [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- 017 Dr. Oz to Oprah and Michael J Fox: "The stem cell debate is dead." [Last Updated On: September 22nd, 2011] [Originally Added On: September 22nd, 2011]
- 018 Manning, Owens Try Stem Cell Therapy [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 019 Jeanne Loring talks about stem cells, part 3 [Last Updated On: October 5th, 2011] [Originally Added On: October 5th, 2011]
- 020 Epidermolysis Bullosa: Corrected iPS Stem Cell-Based Therapy - Video [Last Updated On: October 13th, 2011] [Originally Added On: October 13th, 2011]
- 021 Introduction to Stem Cells - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- 022 Parkinson's Disease: Progress and Promise in Stem Cell Research - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- 023 stem cell research - Video [Last Updated On: December 7th, 2011] [Originally Added On: December 7th, 2011]
- 024 Ian Wilmut discusses stem cell and direct cellular transformation therapy - Video [Last Updated On: December 8th, 2011] [Originally Added On: December 8th, 2011]
- 025 Jeff Bluestone: Immune rejection of stem cell transplants - Video [Last Updated On: December 8th, 2011] [Originally Added On: December 8th, 2011]
- 026 Advances in Stem Cell Research: Shinya Yamanaka - Video [Last Updated On: December 11th, 2011] [Originally Added On: December 11th, 2011]
- 027 2011 Summit: Stem Cells, Reprogramming and Personalized Medicine, Rudolf Jaenisch, MD - Video [Last Updated On: December 14th, 2011] [Originally Added On: December 14th, 2011]
- 028 Parkinson's Disease: Advancing Stem Cell Therapies - 2011 CIRM Grantee Meeting - Video [Last Updated On: January 20th, 2012] [Originally Added On: January 20th, 2012]
- 029 Professor Alan Trounson - World focus on stem cell research - Video [Last Updated On: January 27th, 2012] [Originally Added On: January 27th, 2012]
- 030 Stanford scientists turn skin cells into neural precusors, bypassing stem-cell stage [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- 031 Researchers turn skin cells into neural precusors, bypassing stem-cell stage [Last Updated On: January 31st, 2012] [Originally Added On: January 31st, 2012]
- 032 “Wide-ranging applications for pluripotent stem cells” [Last Updated On: February 2nd, 2012] [Originally Added On: February 2nd, 2012]
- 033 Radiation treatment transforms breast cancer cells into cancer stem cells [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 034 Radiation Treatment Generates Cancer Stem Cells from Less Aggressive Breast Cancer Cells [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 035 Radiation treatment generates cancer stem cells from less aggressive breast cancer cells, study suggests [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 036 Life Technologies Scientist Uma Lakshmipathy presents, "Solving Challenges in the Generation of Induced Pluripotent ... [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 037 Radiation therapy transforms breast cancer cells into cancer stem cells [Last Updated On: February 14th, 2012] [Originally Added On: February 14th, 2012]
- 038 Research and Markets: Primary and Stem Cells: Gene Transfer Technologies and Applications [Last Updated On: February 15th, 2012] [Originally Added On: February 15th, 2012]
- 039 Horizon in new super-cell elite [Last Updated On: February 16th, 2012] [Originally Added On: February 16th, 2012]
- 040 Presentations at the Society of Toxicology Annual Meeting Demonstrate Superior Predictivity of Cellular Dynamics ... [Last Updated On: March 8th, 2012] [Originally Added On: March 8th, 2012]
- 041 New approach to treating type 1 diabetes? Transforming gut cells into insulin factories [Last Updated On: March 12th, 2012] [Originally Added On: March 12th, 2012]
- 042 Gut cells transformed into insulin factories 'could help to treat type I diabetes' [Last Updated On: March 12th, 2012] [Originally Added On: March 12th, 2012]
- 043 A new approach to treating type I diabetes? Gut cells transformed into insulin factories [Last Updated On: March 12th, 2012] [Originally Added On: March 12th, 2012]
- 044 Columbia Researchers Find Potential Role for Gut Cells in Treating Type I Diabetes [Last Updated On: March 12th, 2012] [Originally Added On: March 12th, 2012]
- 045 Study demonstrates cells can acquire new functions through transcriptional regulatory network [Last Updated On: March 14th, 2012] [Originally Added On: March 14th, 2012]
- 046 Gut Cells Turned To Insulin Factories - New Type l Diabetes Treatment [Last Updated On: March 14th, 2012] [Originally Added On: March 14th, 2012]
- 047 Cellular Dynamics Expands Distribution Agreement with iPS Academia Japan, Inc. to Include Distribution of iCell ... [Last Updated On: March 28th, 2012] [Originally Added On: March 28th, 2012]
- 048 :: 20, Apr 2012 :: IBN DISCOVERS HUMAN NEURAL STEM CELLS WITH TUMOR TARGETING ABILITY – A PROMISING DISCOVERY FOR ... [Last Updated On: April 22nd, 2012] [Originally Added On: April 22nd, 2012]
- 049 Human neural stem cells with tumor targeting ability discovered [Last Updated On: April 22nd, 2012] [Originally Added On: April 22nd, 2012]
- 050 IBN Discovers Human Neural Stem Cells, Promising Discovery For Breast Cancer Therapy [Last Updated On: April 22nd, 2012] [Originally Added On: April 22nd, 2012]
- 051 IBN Discovers Human Neural Stem Cells with Tumor Targeting Ability - A Promising Discovery for Breast Cancer Therapy [Last Updated On: April 22nd, 2012] [Originally Added On: April 22nd, 2012]
- 052 VistaGen Secures Key U.S. Patent Covering Stem Cell Technology Methods Used to Test Drug Candidates for Liver Toxicity [Last Updated On: April 25th, 2012] [Originally Added On: April 25th, 2012]
- 053 Improved adult-derived human stem cells have fewer genetic changes than expected [Last Updated On: May 2nd, 2012] [Originally Added On: May 2nd, 2012]
- 054 Researchers restore neuron function to brains damaged by Huntington's disease [Last Updated On: May 31st, 2012] [Originally Added On: May 31st, 2012]
- 055 Cellular Dynamics Launches MyCell™ Services [Last Updated On: June 7th, 2012] [Originally Added On: June 7th, 2012]
- 056 Fate Therapeutics And BD Biosciences Launch BD™ SMC4 To Improve Cellular Reprogramming And IPS Cell Culture Applications [Last Updated On: June 12th, 2012] [Originally Added On: June 12th, 2012]
- 057 Life Technologies and Cellular Dynamics International Partner for Global Commercialization of Novel Stem Cell ... [Last Updated On: June 13th, 2012] [Originally Added On: June 13th, 2012]
- 058 LIFE Focuses on Stem Cell Research - Analyst Blog [Last Updated On: June 20th, 2012] [Originally Added On: June 20th, 2012]
- 059 International Stem Cell Corp Granted Key Patent for Liver Disease Program [Last Updated On: September 30th, 2012] [Originally Added On: September 30th, 2012]
- 060 NeuroGeneration Recruits Top Scientist To Direct New Division of Biotherapeutics and Drug Discovery In La Jolla, CA [Last Updated On: October 5th, 2012] [Originally Added On: October 5th, 2012]
- 061 FRC Supports Alliance Defending Freedom, Jubilee Campaign Cert Petition to Supreme Court on Stem Cell Funding [Last Updated On: October 11th, 2012] [Originally Added On: October 11th, 2012]
- 062 10/11/2012 10:05 JAPAN Nobel Prize for Yamanaka, scientific research and ethics must go hand in hand [Last Updated On: October 11th, 2012] [Originally Added On: October 11th, 2012]
- 063 Read in [Last Updated On: October 12th, 2012] [Originally Added On: October 12th, 2012]
- 064 Induced pluripotent stem cell - Wikipedia, the free encyclopedia [Last Updated On: November 3rd, 2013] [Originally Added On: November 3rd, 2013]
- 065 What are induced pluripotent stem cells or iPS cells? - Stem Cells ... [Last Updated On: November 3rd, 2013] [Originally Added On: November 3rd, 2013]
- 066 Stem Cell Definitions | California's Stem Cell Agency [Last Updated On: November 3rd, 2013] [Originally Added On: November 3rd, 2013]
- 067 iPSCTherapy.com: Induced Pluripotent Stem Cell therapy Information ... [Last Updated On: November 8th, 2013] [Originally Added On: November 8th, 2013]
- 068 Human muscle stem cell therapy gets help from zebrafish [Last Updated On: November 8th, 2013] [Originally Added On: November 8th, 2013]
- 069 Induced pluripotent stem cell therapy - Wikipedia, the free ... [Last Updated On: November 8th, 2013] [Originally Added On: November 8th, 2013]
- 070 IPS Cell Therapy - Genetherapy [Last Updated On: November 8th, 2013] [Originally Added On: November 8th, 2013]
- 071 MD Supervised Stem Cell Therapy [Last Updated On: November 9th, 2013] [Originally Added On: November 9th, 2013]
- 072 Stem Cell Therapy for Neuromuscular Diseases | InTechOpen [Last Updated On: November 23rd, 2013] [Originally Added On: November 23rd, 2013]
- 073 Combining Stem Cell Therapy with Gene Therapy | Boston ... [Last Updated On: November 25th, 2013] [Originally Added On: November 25th, 2013]
- 074 Biomanufacturing center takes central role in developing stem ... [Last Updated On: December 4th, 2013] [Originally Added On: December 4th, 2013]
- 075 Stem Cell Quick Reference - Learn Genetics [Last Updated On: December 6th, 2013] [Originally Added On: December 6th, 2013]
- 076 Induced Pluripotent Stem Cells (iPS) from Human Skin: Probable ... [Last Updated On: December 6th, 2013] [Originally Added On: December 6th, 2013]
- 077 'Something positive for humankind': Girls lend cells to genetic study [Last Updated On: December 13th, 2013] [Originally Added On: December 13th, 2013]
- 078 Stem cell science: Can two girls help change the face of medicine? [Last Updated On: December 13th, 2013] [Originally Added On: December 13th, 2013]
- 079 Okyanos Heart Institute CEO Matt Feshbach Congratulates Japan’s Legislators On Stem Cell Bill And Global Regulatory ... [Last Updated On: December 13th, 2013] [Originally Added On: December 13th, 2013]
- 080 Stem cells for Parkinson's getting ready for clinic [Last Updated On: December 13th, 2013] [Originally Added On: December 13th, 2013]
